Cargando…

The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use

WHAT IS KNOWN AND OBJECTIVE: There is little research on the impact of implementing and monitoring antimicrobial policy in Saudi hospitals. The purpose of this study is to measure the impact of the clinical pharmacist (CP) and infectious disease consultant (ID) interventions on the use of three anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Somai, Niaz, Al-Muhur, Mohammed, Quteimat, Osama, Hamzah, Nashaat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281637/
https://www.ncbi.nlm.nih.gov/pubmed/25561863
http://dx.doi.org/10.1016/j.jsps.2014.02.003
_version_ 1782351023573041152
author Al-Somai, Niaz
Al-Muhur, Mohammed
Quteimat, Osama
Hamzah, Nashaat
author_facet Al-Somai, Niaz
Al-Muhur, Mohammed
Quteimat, Osama
Hamzah, Nashaat
author_sort Al-Somai, Niaz
collection PubMed
description WHAT IS KNOWN AND OBJECTIVE: There is little research on the impact of implementing and monitoring antimicrobial policy in Saudi hospitals. The purpose of this study is to measure the impact of the clinical pharmacist (CP) and infectious disease consultant (ID) interventions on the use of three antimicrobials (caspofungin, imipenem, meropenem) in hospitalized patients in the King Abdullah Medical City hospital. METHODS: The study was carried out in the King Abdullah Medical City, in Mekkah, Saudi Arabia. The hospital is a tertiary center that provides CCU, CSICU, Cardiac, Hematology, ICU, Medical, Neuroscience, Oncology, and specialized surgery services. The use of three antimicrobials (caspofungin, imipenem, meropenem) was reviewed by the clinical pharmacist for four periods, pre and post implementation of policy. Relevant data were collected in four periods. In the first period, before policy implementation, data were collected retrospectively to be used as baseline status reference, and in the three remaining periods that followed data were collected prospectively, and compared to baseline data, to evaluate the role of clinical pharmacist and ID interventions in optimizing antimicrobial therapy. RESULTS AND DISCUSSION: Caspofungin duration of therapy was not affected significantly by the intervention. Statistically significant reduction in antimicrobial therapy duration was observed in imipenem (37%) and meropenem (37%) from baseline, which indicate a better control on antimicrobial use and reduction in antimicrobial resistance. WHAT IS NEW AND CONCLUSION: The impact of the clinical pharmacist and ID interventions, in reducing antimicrobial therapy duration using imipenem and meropenem, is clear from the result presented above. However, lack of restriction and follow up in the antimicrobial policy in case of negative culture makes antimicrobial use uncontrollable in these cases. Establishing good and accepted policy may help reduce consumption and total cost of therapy.
format Online
Article
Text
id pubmed-4281637
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-42816372015-01-05 The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use Al-Somai, Niaz Al-Muhur, Mohammed Quteimat, Osama Hamzah, Nashaat Saudi Pharm J Original Article WHAT IS KNOWN AND OBJECTIVE: There is little research on the impact of implementing and monitoring antimicrobial policy in Saudi hospitals. The purpose of this study is to measure the impact of the clinical pharmacist (CP) and infectious disease consultant (ID) interventions on the use of three antimicrobials (caspofungin, imipenem, meropenem) in hospitalized patients in the King Abdullah Medical City hospital. METHODS: The study was carried out in the King Abdullah Medical City, in Mekkah, Saudi Arabia. The hospital is a tertiary center that provides CCU, CSICU, Cardiac, Hematology, ICU, Medical, Neuroscience, Oncology, and specialized surgery services. The use of three antimicrobials (caspofungin, imipenem, meropenem) was reviewed by the clinical pharmacist for four periods, pre and post implementation of policy. Relevant data were collected in four periods. In the first period, before policy implementation, data were collected retrospectively to be used as baseline status reference, and in the three remaining periods that followed data were collected prospectively, and compared to baseline data, to evaluate the role of clinical pharmacist and ID interventions in optimizing antimicrobial therapy. RESULTS AND DISCUSSION: Caspofungin duration of therapy was not affected significantly by the intervention. Statistically significant reduction in antimicrobial therapy duration was observed in imipenem (37%) and meropenem (37%) from baseline, which indicate a better control on antimicrobial use and reduction in antimicrobial resistance. WHAT IS NEW AND CONCLUSION: The impact of the clinical pharmacist and ID interventions, in reducing antimicrobial therapy duration using imipenem and meropenem, is clear from the result presented above. However, lack of restriction and follow up in the antimicrobial policy in case of negative culture makes antimicrobial use uncontrollable in these cases. Establishing good and accepted policy may help reduce consumption and total cost of therapy. 2014-02-26 2014-12 /pmc/articles/PMC4281637/ /pubmed/25561863 http://dx.doi.org/10.1016/j.jsps.2014.02.003 Text en © 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Original Article
Al-Somai, Niaz
Al-Muhur, Mohammed
Quteimat, Osama
Hamzah, Nashaat
The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title_full The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title_fullStr The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title_full_unstemmed The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title_short The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use
title_sort impact of clinical pharmacist and id intervention in rationalization of antimicrobial use
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281637/
https://www.ncbi.nlm.nih.gov/pubmed/25561863
http://dx.doi.org/10.1016/j.jsps.2014.02.003
work_keys_str_mv AT alsomainiaz theimpactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT almuhurmohammed theimpactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT quteimatosama theimpactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT hamzahnashaat theimpactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT alsomainiaz impactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT almuhurmohammed impactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT quteimatosama impactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse
AT hamzahnashaat impactofclinicalpharmacistandidinterventioninrationalizationofantimicrobialuse